Precision Biosciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL

DURHAM, N.C., March  11, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida Oncology, has been appointed to the company’s Board of Directors.

Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

Precision BioSciences: Consider Taking Up A Small Position

Cellectis SA

Calyxt

Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.

These Gene-Editing Pioneers Are Making Bold Bets in Agriculture

-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020-

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

Precision BioSciences Makes Impressive Progress On Mission To Change CAR-T Therapy Landscape

GameStop

International Flavors & Fragrances

Find out why one of these stocks lost more than half its value.

Why International Flavors & Fragrances, Precision BioSciences, and GameStop Slumped Today

Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.

No CRISPR Required: This Forgotten Gene Editing is Up 50% in 5 Weeks

Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.

Here's Why Shares of This Gene Editing Pioneer Are Collapsing Today

Forty Seven Inc

Mustang Bio

Roche Holding AG

TG Therapeutics

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

5 Stocks Moving On ASH Presentations

Shares of Precision BioSciences Inc.  are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell therapy.

Precision BioSciences stock rises on early-stage CAR-T trial data

- PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease-

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic C

As of late, it has definitely been a great time to be an investor in Precision BioSciences, Inc. (DTIL).

Precision BioSciences, Inc. (DTIL) Shares March Higher, Can It Continue?

The gene-editing company rallied investors around intriguing clinical data released earlier this month, and the rally hasn't stopped.

Here's Why Precision BioSciences Is Soaring Today

DURHAM, N.C., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that Kevin J. Buehler, former CEO of Alcon Laboratories, has been appointed to its Board of Directors, which took effect following the company’s third quarter board meeting held on November 8, 2019.

Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors

Fastly

Levi Strauss

Uber

Transmedics Group Inc

The IPO market is on fire right now. But not all the new IPO stocks make for promising investing opportunities to say the least.

5 IPO Stocks to Buy — According to Wall Street Analysts

Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.

Is the Newest Gene Editing Stock a Buy?

News for Precision Biosciences Stock (DTIL)